This is relevant in the setting of AAA, as current pharmacological approaches (e.g., antihypertensive and antiplatelet drugs, statins, ACE inhibitors, and renin–angiotensin inhibitors) do not target AAA development but co-morbidities and risk factors. Here, REN is linked to triple-A syndrome.